72.18
Schlusskurs vom Vortag:
$72.96
Offen:
$73.16
24-Stunden-Volumen:
300.14K
Relative Volume:
0.83
Marktkapitalisierung:
$1.66B
Einnahmen:
$923.71M
Nettoeinkommen (Verlust:
$84.68M
KGV:
18.31
EPS:
3.9419
Netto-Cashflow:
$182.81M
1W Leistung:
-2.46%
1M Leistung:
-1.20%
6M Leistung:
-2.74%
1J Leistung:
-19.02%
Ani Pharmaceuticals Inc Stock (ANIP) Company Profile
Firmenname
Ani Pharmaceuticals Inc
Sektor
Telefon
(609) 759-1810
Adresse
104 CARNEGIE CENTER DRIVE SUITE 300, PRINCETON, MN
Compare ANIP vs TAK, TEVA, HLN, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
ANIP
Ani Pharmaceuticals Inc
|
72.18 | 1.70B | 923.71M | 84.68M | 182.81M | 3.9419 |
|
TAK
Takeda Pharmaceutical Co Adr
|
17.86 | 60.23B | 29.91B | 1.30B | 3.49B | 0.4056 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
39.53 | 45.71B | 17.53B | 1.58B | 444.18M | 1.3457 |
|
HLN
Haleon Plc Adr
|
8.80 | 40.72B | 14.54B | 2.22B | 2.58B | 0.4871 |
|
ZTS
Zoetis Inc
|
69.69 | 29.36B | 9.51B | 2.64B | 2.14B | 6.0361 |
|
UTHR
United Therapeutics Corp
|
541.70 | 20.39B | 3.17B | 1.29B | 1.01B | 27.09 |
Ani Pharmaceuticals Inc Stock (ANIP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-03-14 | Eingeleitet | Jefferies | Buy |
| 2025-03-12 | Eingeleitet | JP Morgan | Overweight |
| 2024-12-11 | Eingeleitet | Leerink Partners | Outperform |
| 2024-10-11 | Eingeleitet | Piper Sandler | Overweight |
| 2024-03-15 | Eingeleitet | CapitalOne | Overweight |
| 2023-08-22 | Bestätigt | H.C. Wainwright | Buy |
| 2023-03-01 | Eingeleitet | Guggenheim | Buy |
| 2022-09-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-11-02 | Eingeleitet | Truist | Buy |
| 2020-05-07 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2019-09-12 | Eingeleitet | Guggenheim | Buy |
| 2019-05-10 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2017-10-16 | Bestätigt | Canaccord Genuity | Buy |
| 2017-07-31 | Eingeleitet | Canaccord Genuity | Buy |
| 2017-02-22 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2016-06-23 | Eingeleitet | Raymond James | Strong Buy |
| 2016-05-24 | Herabstufung | Standpoint Research | Buy → Hold |
| 2015-11-13 | Eingeleitet | Standpoint Research | Buy |
| 2015-09-28 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2015-08-05 | Bestätigt | Oppenheimer | Outperform |
| 2015-08-04 | Bestätigt | ROTH Capital | Neutral |
| 2015-07-31 | Bestätigt | Oppenheimer | Outperform |
| 2015-07-15 | Bestätigt | ROTH Capital | Neutral |
| 2015-06-23 | Bestätigt | Oppenheimer | Outperform |
| 2015-05-18 | Bestätigt | ROTH Capital | Neutral |
| 2015-05-06 | Bestätigt | Oppenheimer | Outperform |
| 2015-04-10 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2015-02-26 | Bestätigt | ROTH Capital | Buy |
| 2015-02-18 | Bestätigt | Oppenheimer | Outperform |
Alle ansehen
Ani Pharmaceuticals Inc Aktie (ANIP) Neueste Nachrichten
Form 4 ANI Pharmaceuticals Inc For: 1 October By Investing.com - Investing.com Australia
Ani Pharmaceuticals SVP & CFO Stephen Carey sells $208,050 in stock - Investing.com Nigeria
ANI Pharmaceuticals, Inc. (ANIP) Stock Forecasts - Yahoo! Finance Canada
ANI Pharmaceuticals (NASDAQ:ANIP) Stock: Insider Stephen Carey Sells 2,850 Shares - MarketBeat
Amphastar Pharmaceuticals, Inc. (AMPH) Stock Price, News, Quote & History - Yahoo! Finance Canada
After selling 2,850 shares, ANI Pharmaceuticals (ANIP) CFO holds 168,993 shares. - Stock Titan
ANI Pharmaceuticals Announces New Fluocinolone Acetonide - GlobeNewswire
Implied Volatility Surging for ANI Pharmaceuticals Stock Options - TradingView
183,066 Shares of ANI Pharmaceuticals, Inc. $ANIP Acquired by Bank of America Corp DE - MarketBeat
ANIP5868601 Bond Profile: Coupon and Redemption - TradingView
ANI Pharmaceuticals: Cortrophin’s Q4 Test, With Generics Funding The Build (NASDAQ:ANIP) - Seeking Alpha
ANI Pharmaceuticals, Inc. (ANIP) Stock forecasts - Yahoo Finance Singapore
Ocular Therapeutix and ANI Pharmaceuticals Stocks Trade Down, What You Need To Know - Yahoo Finance
ANI Pharmaceuticals, Inc. (ANIP) Stock Price, News, Quote & History - Yahoo! Finance Canada
ANI Pharmaceuticals Initiated at Perform by Oppenheimer - Moomoo
Oppenheimer initiates ANI Pharmaceuticals stock with Perform rating By Investing.com - Investing.com Nigeria
ANI Pharmaceuticals gets FDA approval for generic everolimus By Investing.com - Investing.com South Africa
ANI Pharmaceuticals gets FDA approval for generic everolimus - Investing.com
Oppenheimer initiates ANI Pharmaceuticals stock with Perform rating - Investing.com
ANI Pharmaceuticals Receives FDA Approval for Generic Everolimus Tablets for Oral Suspension - Quiver Quantitative
ANI Pharmaceuticals Announces the FDA Approval of Everolimus Tablets for Oral Suspension - GlobeNewswire
Oppenheimer Initiates ANI Pharmaceuticals at Perform With $85 Price Target - Yahoo Finance
ANI Pharmaceuticals (ANIP) Reports Next Week: Wall Street Expects Earnings Growth - Eastern Progress
ANI Pharmaceuticals (ANIP) President & CEO Nikhil Lalwani Sells 5,400 Shares - GuruFocus
Insider Selling: ANI Pharmaceuticals (NASDAQ:ANIP) CEO Sells $383,400.00 in Stock - MarketBeat
ANI Pharmaceuticals (ANIP) CEO sells 5,400 shares in pre-set trading plan - Stock Titan
Ani Pharmaceuticals director Thoma sells $71,530 in shares By Investing.com - Investing.com South Africa
ANI Pharmaceuticals (NASDAQ: ANIP) insider lines up $380,000 stock sale for 2026 - Stock Titan
ANI Pharmaceuticals Executive Cook Meredith Sells 500 Shares at $70.79 Each (NASDAQ: ANIP) - Kalkine Media
Squarepoint Ops LLC Sells 37,088 Shares of ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
Ani Pharmaceuticals’ Meredith Cook sells $35,395 in common stock By Investing.com - Investing.com Canada
Ani Pharmaceuticals’ Meredith Cook sells $35,395 in common stock - Investing.com
ANI Pharmaceuticals (ANIP) Insider Sale: SVP, General Counsel & Secretary Meredith Cook Sells 500 Shares - GuruFocus
Insider Selling: ANI Pharmaceuticals (NASDAQ:ANIP) VP Sells $35,395.00 in Stock - MarketBeat
Amundi Boosts Stock Position in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
VIRGINIA RETIREMENT SYSTEMS ET Al Acquires New Position in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
ANI Pharmaceuticals (NASDAQ: ANIP) director plans $71K share sale - Stock Titan
WINTON GROUP Ltd Takes $4.56 Million Position in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
ANI Pharmaceuticals at Wells Fargo conference: rare disease push gains pace - Investing.com
ANIP: Record growth in rare disease and generics, with strong financials and strategic expansion - TradingView
ANI Pharmaceuticals stock hits 52-week low at 70.03 USD By Investing.com - Investing.com Nigeria
ETFs Investing in ANI Pharmaceuticals, Inc. Stocks - TradingView
ANI Pharmaceuticals (NASDAQ:ANIP) Sets New 52-Week LowTime to Sell? - MarketBeat
ANI Pharmaceuticals stock hits 52-week low at 70.03 USD - investing.com
ANI Pharmaceuticals (NASDAQ:ANIP) Earns Outperform Rating from Analysts at Leerink Partners - MarketBeat
Legal & General Group Plc Buys Shares of 45,075 ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
Finanzdaten der Ani Pharmaceuticals Inc-Aktie (ANIP)
Umsatz
Nettogewinn
Free Cashflow
ENV
Ani Pharmaceuticals Inc-Aktie (ANIP) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Lalwani Nikhil | PRESIDENT & CEO |
Sep 15 '26 |
Sale |
71.00 |
5,400 |
383,400 |
339,089 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):